Medtronic spends $326 million to buy BPH (benign prostatic hyperplasia) company VidaMed
This article was originally published in Clinica
Executive Summary
Medtronic is expanding its urology business with the $326 million acquisition of VidaMed, which has a transurethral needle ablation (TUNA) system for the treatment of benign prostatic hyperplasia (BPH). Under the terms of the deal, each VidaMed shareholder will receive $7.91 per share in cash on consummation of the transaction. This represents a 40% premium on VidaMed's closing price of $5.67 the day before the deal was announced.